Literature DB >> 11997448

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.

Jay A Grobler1, Kara Stillmock, Binghua Hu, Marc Witmer, Peter Felock, Amy S Espeseth, Abigail Wolfe, Melissa Egbertson, Michele Bourgeois, Jeffrey Melamed, John S Wai, Steve Young, Joseph Vacca, Daria J Hazuda.   

Abstract

The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent reactions, 3' end processing and strand transfer. Compounds that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication. To characterize the molecular basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs. These studies focused on investigating the role of the conserved carboxylate and metal binding. We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor. Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg(2+). The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical metal cofactor(s). These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997448      PMCID: PMC124459          DOI: 10.1073/pnas.092056199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases.

Authors:  F Dyda; A B Hickman; T M Jenkins; A Engelman; R Craigie; D R Davies
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

2.  A novel assay for the DNA strand-transfer reaction of HIV-1 integrase.

Authors:  D J Hazuda; J C Hastings; A L Wolfe; E A Emini
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

3.  A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro.

Authors:  V Ellison; P O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

4.  Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1.

Authors:  G Englund; T S Theodore; E O Freed; A Engelman; M A Martin
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds.

Authors:  J Tomassini; H Selnick; M E Davies; M E Armstrong; J Baldwin; M Bourgeois; J Hastings; D Hazuda; J Lewis; W McClements
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Formation of a stable complex between the human immunodeficiency virus integrase protein and viral DNA.

Authors:  C Vink; R A Lutzke; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

7.  The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn(II) rather than Mg(II).

Authors:  I K Pemberton; M Buckle; H Buc
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

8.  Substrate specificity of recombinant human immunodeficiency virus integrase protein.

Authors:  R L LaFemina; P L Callahan; M G Cordingley
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  DNA binding properties of the integrase proteins of human immunodeficiency viruses types 1 and 2.

Authors:  D C van Gent; Y Elgersma; M W Bolk; C Vink; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

10.  Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.

Authors:  M Wiskerchen; M A Muesing
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  112 in total

1.  HIV-1 Integrase Inhibitor-Inspired Antibacterials Targeting Isoprenoid Biosynthesis.

Authors:  Yonghui Zhang; Kai Li; Wei Zhu; Yi-Liang Liu; Rong Cao; Ran Pang; Eunhae Lee; Jordan Axelson; Mary Hensler; Ke Wang; Katie J Molohon; Yang Wang; Douglas A Mitchell; Victor Nizet; Eric Oldfield
Journal:  ACS Med Chem Lett       Date:  2012-04-03       Impact factor: 4.345

2.  Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study.

Authors:  Chenzhong Liao; Marc C Nicklaus
Journal:  ChemMedChem       Date:  2010-07-05       Impact factor: 3.466

Review 3.  Allosteric inhibitor development targeting HIV-1 integrase.

Authors:  Laith Q Al-Mawsawi; Nouri Neamati
Journal:  ChemMedChem       Date:  2011-01-12       Impact factor: 3.466

4.  Switching between raltegravir resistance pathways analyzed by deep sequencing.

Authors:  Rithun Mukherjee; Shane T Jensen; Frances Male; Kyle Bittinger; Richard L Hodinka; Michael D Miller; Frederic D Bushman
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

5.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

Review 6.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

8.  HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.

Authors:  Vasu Nair; Guochen Chi; Roger Ptak; Nouri Neamati
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

9.  Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site.

Authors:  Daniel M Himmel; Karen A Maegley; Tom A Pauly; Joseph D Bauman; Kalyan Das; Chhaya Dharia; Arthur D Clark; Kevin Ryan; Michael J Hickey; Robert A Love; Stephen H Hughes; Simon Bergqvist; Eddy Arnold
Journal:  Structure       Date:  2009-12-09       Impact factor: 5.006

10.  Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design.

Authors:  Rajeshri G Karki; Yun Tang; Terrence R Burke; Marc C Nicklaus
Journal:  J Comput Aided Mol Des       Date:  2005-06-27       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.